AR087371A1 - Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos - Google Patents
Formulaciones de (trimetoxifenilamino)pirimidinilo, metodosInfo
- Publication number
- AR087371A1 AR087371A1 ARP120102755A ARP120102755A AR087371A1 AR 087371 A1 AR087371 A1 AR 087371A1 AR P120102755 A ARP120102755 A AR P120102755A AR P120102755 A ARP120102755 A AR P120102755A AR 087371 A1 AR087371 A1 AR 087371A1
- Authority
- AR
- Argentina
- Prior art keywords
- trimetoxifenilamino
- pyrimidinyl
- formulations
- methods
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- -1 PYRIMIDINYL Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas que comprenden más de un 15% p/p del compuesto de fórmula (1), según se define en la presente, y/o un hidrato de este y una cantidad de uno o más agentes efervescentes que sea suficiente para proporcionar una disolución satisfactoria in vitro; y que comprenden además uno o más ingredientes farmacéuticamente aceptables; y procesos para obtenerlas.Reivindicación 5: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque el agente efervescente es hidrogenocarbonato de sodio. Reivindicación 6: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque cada X+ en el compuesto de fórmula (1) representa un catión de sodio (Na+).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512621P | 2011-07-28 | 2011-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087371A1 true AR087371A1 (es) | 2014-03-19 |
Family
ID=46875902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102755A AR087371A1 (es) | 2011-07-28 | 2012-07-27 | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8771648B2 (es) |
| EP (1) | EP2736487B2 (es) |
| JP (1) | JP6019116B2 (es) |
| KR (2) | KR102090440B1 (es) |
| CN (1) | CN103826610B (es) |
| AR (1) | AR087371A1 (es) |
| AU (1) | AU2012288632B2 (es) |
| BR (1) | BR112014001999B1 (es) |
| CA (1) | CA2843138C (es) |
| CY (1) | CY1122596T1 (es) |
| DK (1) | DK2736487T4 (es) |
| EA (1) | EA028432B1 (es) |
| ES (1) | ES2710423T5 (es) |
| FI (1) | FI2736487T4 (es) |
| HR (1) | HRP20190186T4 (es) |
| HU (1) | HUE042611T2 (es) |
| LT (1) | LT2736487T (es) |
| MX (1) | MX339685B (es) |
| PL (1) | PL2736487T5 (es) |
| PT (1) | PT2736487T (es) |
| RS (1) | RS58433B2 (es) |
| SI (1) | SI2736487T2 (es) |
| SM (1) | SMT201900071T1 (es) |
| TR (1) | TR201901792T4 (es) |
| TW (1) | TW201311251A (es) |
| UY (1) | UY34223A (es) |
| WO (1) | WO2013014454A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163902B2 (en) * | 2006-11-21 | 2012-04-24 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| HRP20190186T4 (hr) | 2011-07-28 | 2024-12-20 | Rigel Pharmaceuticals, Inc. | Nove formulacije (trimetoksifenilamino)pirimidinila |
| CA2979990C (en) | 2015-04-02 | 2023-03-28 | Stora Enso Oyj | An activated lignin composition, a method for the manufacturing thereof and use thereof |
| US20180296579A1 (en) | 2015-04-24 | 2018-10-18 | Rigel Pharmaceuticals, Inc. | Methods of treating ibrutinib-resistant disease |
| SE542795C2 (en) | 2018-10-08 | 2020-07-07 | Stora Enso Oyj | Process for preparing a resin |
| RS66027B1 (sr) | 2020-07-07 | 2024-11-29 | Celgene Corp | Farmaceutske kompozicije koje sadrže (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi)m etil)benzil)piperazin-1-il)-3-fluorbenzonitril i metode njihove upotrebe |
| EP4185126A1 (en) * | 2020-07-24 | 2023-05-31 | DSM IP Assets B.V. | New fast dissolvable tablets |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DE60221787T2 (de) † | 2002-03-04 | 2008-06-05 | Orbus Pharma Inc. | Zusammensetzungen mit schneller Freisetzung enthaltend Cefuroxime Axetil |
| ATE451104T1 (de) | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| EP1663242B1 (en) | 2003-08-07 | 2011-04-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| US20060051406A1 (en) * | 2004-07-23 | 2006-03-09 | Manjeet Parmar | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| CA2580838A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| KR100716389B1 (ko) † | 2004-11-23 | 2007-05-11 | 동화약품공업주식회사 | Ｎ-히드록시－４－｛５－［４－（5－이소프로필－２－메틸－１,３－티아졸－4－일）페녹시］펜톡시｝벤즈아미딘 ２메탄술폰산염 |
| EP2161275A1 (en) * | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| CA2631875A1 (en) * | 2005-12-06 | 2007-10-04 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| US7659280B2 (en) * | 2006-02-17 | 2010-02-09 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
| US20090048214A1 (en) * | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
| US8163902B2 (en) * | 2006-11-21 | 2012-04-24 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US20090012045A1 (en) * | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
| WO2009029682A1 (en) * | 2007-08-28 | 2009-03-05 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
| CA2704474C (en) | 2007-11-07 | 2016-04-26 | Rigel Pharmaceuticals, Inc. | Wet granulation using a water sequestering agent |
| AU2009215430B2 (en) | 2008-02-22 | 2015-02-12 | Rigel Pharmaceuticals, Inc. | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
| UA108077C2 (xx) * | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
| WO2011009075A2 (en) | 2009-07-17 | 2011-01-20 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| WO2011063241A1 (en) | 2009-11-20 | 2011-05-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| ES2562419T3 (es) | 2010-04-13 | 2016-03-04 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos |
| HRP20190186T4 (hr) | 2011-07-28 | 2024-12-20 | Rigel Pharmaceuticals, Inc. | Nove formulacije (trimetoksifenilamino)pirimidinila |
-
2012
- 2012-07-26 HR HRP20190186TT patent/HRP20190186T4/hr unknown
- 2012-07-26 WO PCT/GB2012/051791 patent/WO2013014454A1/en not_active Ceased
- 2012-07-26 EP EP12759802.7A patent/EP2736487B2/en active Active
- 2012-07-26 SM SM20190071T patent/SMT201900071T1/it unknown
- 2012-07-26 TR TR2019/01792T patent/TR201901792T4/tr unknown
- 2012-07-26 FI FIEP12759802.7T patent/FI2736487T4/fi active
- 2012-07-26 MX MX2014001065A patent/MX339685B/es active IP Right Grant
- 2012-07-26 LT LTEP12759802.7T patent/LT2736487T/lt unknown
- 2012-07-26 DK DK12759802.7T patent/DK2736487T4/da active
- 2012-07-26 PT PT12759802T patent/PT2736487T/pt unknown
- 2012-07-26 PL PL12759802.7T patent/PL2736487T5/pl unknown
- 2012-07-26 SI SI201231519T patent/SI2736487T2/sl unknown
- 2012-07-26 EA EA201490363A patent/EA028432B1/ru unknown
- 2012-07-26 CN CN201280046605.3A patent/CN103826610B/zh active Active
- 2012-07-26 RS RS20190146A patent/RS58433B2/sr unknown
- 2012-07-26 CA CA2843138A patent/CA2843138C/en active Active
- 2012-07-26 ES ES12759802T patent/ES2710423T5/es active Active
- 2012-07-26 UY UY0001034223A patent/UY34223A/es unknown
- 2012-07-26 KR KR1020197027074A patent/KR102090440B1/ko active Active
- 2012-07-26 BR BR112014001999-1A patent/BR112014001999B1/pt active IP Right Grant
- 2012-07-26 KR KR1020147004810A patent/KR102024120B1/ko active Active
- 2012-07-26 AU AU2012288632A patent/AU2012288632B2/en active Active
- 2012-07-26 JP JP2014522154A patent/JP6019116B2/ja active Active
- 2012-07-26 HU HUE12759802A patent/HUE042611T2/hu unknown
- 2012-07-27 AR ARP120102755A patent/AR087371A1/es not_active Application Discontinuation
- 2012-07-27 TW TW101127261A patent/TW201311251A/zh unknown
- 2012-07-27 US US13/559,805 patent/US8771648B2/en active Active
-
2014
- 2014-05-29 US US14/290,494 patent/US8951504B2/en active Active
-
2019
- 2019-02-06 CY CY20191100159T patent/CY1122596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| PE20130217A1 (es) | Composiciones farmaceuticas y metodos para su elaboracion | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| BR112014009031A2 (pt) | formulações de etanercept estabilizadas com íons de metais | |
| BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| MX381600B (es) | Composicion que comprende un agente de control biologico y un fungicida. | |
| BR112014029754B1 (pt) | soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| AR094012A1 (es) | Composiciones estables con peroxido para el cuidado oral | |
| MX374628B (es) | Formulacion que comprende un agente hipolipidemico. | |
| AR083035A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| MX356951B (es) | Estabilizacion de fsh. | |
| MX2015008704A (es) | Limpiador de horno de dosis unitaria de tableta solida. | |
| AR093126A1 (es) | Formulaciones de liberacion modificada para oprozomib | |
| CL2010001566A1 (es) | Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune. | |
| AR088918A1 (es) | Composiciones antitranspirantes anhidras | |
| BR112013028607A2 (pt) | composições sólidas contendo éter glicólico e água | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| MX2017007741A (es) | Formulaciones de calcio y fosfato para inflamacion oral. | |
| CO2019003761A2 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos | |
| RU2013110517A (ru) | Средство для профилактики или лечения неалкогольного стеатогепатита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |